Korea Health Industry Development Institute Holds 'Transformative Innovation Policy Roundtable Meeting'

[Asia Economy Reporter Chunhee Lee] The Korea Health Industry Development Institute announced on the 1st that it will jointly hold the ‘Transformative Innovation Policy Roundtable Meeting’ with the Korea Institute of Science and Technology Planning and Evaluation and the National Academy of Medicine of Korea.

Held in conjunction with the ‘2022 Seoul Bioeconomy Forum,’ this event was organized to understand the policy context of major countries regarding the government’s key national agenda items such as the ‘Mission-Oriented Innovation Policy (MOIP)’ and the ‘Korean-style ARPA-H,’ and to gain insights for policy design and implementation. It is sponsored by the Ministry of Health and Welfare, Osong Advanced Medical Foundation, and Daegu-Gyeongbuk Advanced Medical Foundation.

The event features international experts including Dr. Tara A. Schwetz, Principal Deputy Director of the U.S. National Institutes of Health (NIH); Dr. Adam Russell, Deputy Director of ARPA-H; Dr. Regina E. Dugan, CEO of Wellcome Leap; and Dr. Nakanishi Makoto, PM of Japan’s Moonshot Program (Professor at the University of Tokyo), as well as domestic experts such as Kim Young-ok, Planning Director of the Development Institute; Jeong Byeong-seon, President of the Korea Institute of Science and Technology Planning and Evaluation; and Wang Gyu-chang, President of the National Academy of Medicine of Korea.

The event consists of two sessions. The first session, led by President Jeong Byeong-seon, will include presentations and discussions on MOIP, and the second session, led by Professor Seon-gyeong, Emeritus Professor at Korea University College of Medicine, will include presentations and discussions on the Korean-style ARPA-H.

Kim Young-ok, Planning Director of the Development Institute, stated, “DARPA is a transformative research innovation model benchmarked worldwide and is emerging as a powerful alternative to solve health and medical challenges, including health security, centered on leading countries such as the U.S. and the U.K. In the post-COVID-19 era, Korea’s health and medical R&D policy must also shift toward mission-oriented and challenging directions. We hope this will be a valuable opportunity to gather the experiences and wisdom of experts from various countries to prepare a desirable Korean-style ARPA-H policy.”

This content was produced with the assistance of AI translation services.